Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Search for:

Recent Posts

Avatrombopag (Doptelet®): First Global Approval – Reducing the bleeding risks of invasive procedures in patients with Chronic Liver Disease
Erenumab (AIMOVIG™): First Global Approval in US followed by Positive CHMP Opinion – Once-monthly prophylactic approach for adults with Migraine
Durvalumab (Imfinzi®): CHMP Positive Opinion for NSCLC in Europe
Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada
Durvalumab (IMFINZI®): Follow up Approval for NSCLC in Japan

Recent Comments

	Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
	Durvalumab (IMFENZI®… on Durvalumab (IMFINZI®): Follow…
	Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
	Baricitinib (Olumian… on Baricitinib (Olumiant™): First…
	Revolution, innovati… on Using state-of-the-art technol…

Archives

Categories

Adis (81)
Adis Journals (89)
Adis Pharmacovigilance (21)
AdisInsight (92)
Uncategorized (2)

July 5, 2017 2551 × 1914

2.Co-editorsofnewacademicbook

Leave a Reply Cancel reply

Powered by WordPress.com.